A Randomised, Double-Blind, Intra-Individual Controlled, Single-Center, Phase I Healthy Volunteer Study to Determine the Pharmacodynamic and Safety of MT10107 (Botulinum Type A Neurotoxin) in Comparison to BOTOX®.

Trial Profile

A Randomised, Double-Blind, Intra-Individual Controlled, Single-Center, Phase I Healthy Volunteer Study to Determine the Pharmacodynamic and Safety of MT10107 (Botulinum Type A Neurotoxin) in Comparison to BOTOX®.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Spasm
  • Focus First in man; Pharmacodynamics
  • Sponsors Medy-Tox
  • Most Recent Events

    • 11 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Korean Clinical Trials Register.
    • 13 Feb 2013 Planned end date changed from 21 Mar 2013 to 28 Feb 2013 as reported by Korean Clinical Trials Register.
    • 13 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by Korean Clinical Trials Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top